Am J Perinatol 2021; 38(11): 1109-1116
DOI: 10.1055/s-0041-1728827
SMFM Fellowship Series Article

Pragmatic Experience with Risk-based versus Universal Hepatitis C Screening in Pregnancy: Detection of Infection and Postpartum Linkage to Care

Elisa T. Bushman
1  Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, Alabama
2  Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama
,
Lakshmi Subramani
3  University of Alabama Birmingham School of Medicine, Birmingham, Alabama
,
Aalok Sanjanwala
1  Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, Alabama
2  Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama
,
Jodie Dionne-Odom
4  Department of Medicine, University of Alabama Birmingham, Birmingham, Alabama
,
Ricardo Franco
4  Department of Medicine, University of Alabama Birmingham, Birmingham, Alabama
,
John Owen
1  Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, Alabama
2  Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama
,
Akila Subramaniam
1  Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, Alabama
2  Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama
› Institutsangaben

Abstract

Objective Despite the Centers for Disease Control and Prevention (CDC) and U.S. Preventive Services Task Force (USPSTF) recommending universal hepatitis C virus (HCV) screening in pregnancy Society for Maternal-Fetal Medicine (SMFM) and American College of Obstetricians and Gynecologists (ACOG) continue to endorse risk-based screening for HCV in pregnancy. We hypothesized that universal screening is associated with increased HCV diagnosis and postpartum linkage to HCV care compared with risk-based screening.

Study Design This retrospective cohort study included pregnant women screened for HCV at a single tertiary-care center. We defined two cohorts: women managed with risk-based (January 2014–October 2016) or universal HCV screening (November 2016–December 2018). Screening was performed with ELISA antibody testing and viremia confirmed with HCV ribonucleic acid (RNA) polymerase chain reaction (PCR). Primary outcomes were the rate of HCV screen positivity and postpartum linkage to care.

Results From 2014 to 2018, 16,489 women delivered at our institution, of whom 166 screened positive for HCV. A total of 7,039 pregnant women were screened for HCV: 266 with risk-based and 6,773 with universal screening; 29% (76/266) were positive HCV antibody screening (HCVAb + ) in the risk-based cohort and 1.3% (90/6,773) in the universal cohort. HCVAb+ women in the risk-based cohort were more likely to have a positive drug screen. Only 69% (62/90) of HCVAb+ women in the universal cohort met the criteria for risk-based testing. Of the remaining 28 women, 6 (21%) had active viremia (HCV RNA+). Of the 166 HCVAb+ women, 64% (103/166) were HCV RNA+—51 of 266 (19%) in the risk-based and 52 of 6,773 (0.8%) in the universal cohort. Of HCVAb+ women, 75% (125/166) were referred postpartum for HCV evaluation and 27% (34/125) were linked to care. Only 9% (10/103) of women with viremia initiated treatment within 1 year of delivery.

Conclusion Universal HCV screening in pregnancy identified an additional 31% of HCVAb+ women compared with risk-based screening. Given low rates of HCV follow-up and treatment regardless of screening modality, further studies are needed to address barriers to postpartum linkage to care.

Key Points

  • Ideal screening for HCV in pregnancy is unknown.

  • We explore screening strategies in pregnancy to linkage to HCV care.

  • Regardless of screening strategy there is low rates of postpartum linkage to HCV care.

Note

This paper was previously presented at the 2020 SMFM 40th Annual Scientific Meeting.




Publikationsverlauf

Eingereicht: 20. November 2020

Angenommen: 02. März 2021

Publikationsdatum:
02. Mai 2021 (online)

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA